Equities analysts predict that Crispr Therapeutics AG (NASDAQ:CRSP) will post sales of $59.43 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Crispr Therapeutics’ earnings. The highest sales estimate is $76.70 million and the lowest is $14.30 million. Crispr Therapeutics posted sales of $120,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 49,425%. The firm is expected to issue its next earnings report on Monday, February 24th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $272.00 million for the current financial year, with estimates ranging from $226.90 million to $289.27 million. For the next year, analysts forecast that the firm will report sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The company had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million.

CRSP has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Roth Capital boosted their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. TheStreet upgraded shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $104.00 target price on shares of Crispr Therapeutics in a research report on Monday, December 16th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Crispr Therapeutics has an average rating of “Buy” and an average target price of $71.38.

CRSP traded down $0.94 during trading on Thursday, reaching $60.91. 1,392,153 shares of the company’s stock were exchanged, compared to its average volume of 723,478. Crispr Therapeutics has a one year low of $27.11 and a one year high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $3.64 billion, a PE ratio of -17.70 and a beta of 3.30. The firm has a fifty day moving average price of $65.68 and a two-hundred day moving average price of $50.89.

In other news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the transaction, the director now owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 over the last three months. Insiders own 21.40% of the company’s stock.

Several institutional investors have recently modified their holdings of CRSP. Nikko Asset Management Americas Inc. grew its holdings in shares of Crispr Therapeutics by 48.4% in the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after purchasing an additional 906,006 shares during the last quarter. Orbimed Advisors LLC bought a new stake in Crispr Therapeutics in the third quarter valued at $21,167,000. Price T Rowe Associates Inc. MD boosted its holdings in Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after acquiring an additional 121,176 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after acquiring an additional 116,540 shares in the last quarter. Finally, Balyasny Asset Management LLC bought a new stake in Crispr Therapeutics in the second quarter valued at $5,165,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: Trading Stocks – What are percentage gainers?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.




Source link